B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Mayo Clinic
Mayo Clinic
National Cancer Institute (NCI)
City of Hope Medical Center
Roswell Park Cancer Institute
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)